Botulism is both an old and an emerging disease. Over 100 years ago, the classic food-borne type was found to be caused by ingesting contaminated food containing the toxin produced by a bacteria. In the first half of the 20th century a second form, wound botulism, was discovered. Three additional forms (infant, hidden, and inadvertent) were first described in the last quarter of the 20th century. Our understanding of how botulinum toxin blocks the release of acetylcholine at the neuromuscular junction has been clarified in the past 10 years. In the past 20 years, we have witnessed one of the strangest of all ironies in the history of medicine. The very lethal botulinum toxin is now being used as a treatment in an expanding list of disorders. Research is advancing in several directions. These new avenues include improved methods of preventing and treating botulism and additional novel uses of botulinum toxin as a therapeutic agent. In this article, the five clinical forms of botulism, the actions of botulinum toxins, electrodiagnostic methods, treatments, and possible future directions are discussed.
KEYWORDS
Botulism - botulinum toxin - acetylcholine - paralysis - electrodiagnosis - antitoxin - new forms
REFERENCES
1
Cherington M.
Clinical spectrum of botulism.
Muscle Nerve.
1998;
21
701-710
2
Scott A B.
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
J Pediatr Ophthalmol Strabismus.
1980;
17
21-25
3
Chang M, Glynn K, Groseclose S L.
Endemic, notifiable bioterrorism-related diseases, Unites States 1992-1999.
Emerg Infect Dis.
2003;
9
556-564
4
Han S Z, Alfano M C, Psoter W J, Rekow E D.
Bioterrorism and catastrophe response.
J Am Dent Assoc.
2003;
134
745-752
5
Lamanna C.
The most poisonous poison.
Science.
1959;
130
763-772
6
Burningham M D, Walter F G, Mechem C et al..
Wound botulism.
Ann Emerg Med.
1994;
24
1184-1187
7 Hughes J M. Botulism. In: Scheid WM, Whitley RJ, Durack DT Infections of the Central Nervous System. New York; Raven Press 1991: 150-153
8
Schantz E J, Johnson E A.
Botulinum toxin: the story of its development for the treatment of human disease.
Perspect Biol Med.
1997;
40
317-327
9
Foran P G, Davletov B, Meunier F A.
Getting muscles moving again after botulinum toxin: novel therapeutic challenges.
Trends Mol Med.
2003;
9
291-298
10
Maselli R A.
Pathogenesis of human botulism.
Ann N Y Acad Sci.
1998;
841
122-139
11
Schiavo G, Benfenati F, Poulain B et al..
Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.
Nature.
1992;
359
832-835
12
Barnes M.
Botulinum toxin: mechanisms of action and clinical use in spasticity.
J Rehabil Med.
2003;
41(suppl)
56-59
13
Cherington M.
Botulism: ten year experience.
Arch Neurol.
1974;
30
432-437
14
Woodruff B A, Griffin P M, McCroskey L M et al..
Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States 1975-1988.
J Infect Dis.
1992;
166
1281-1286
15 Beller M. Available at: www.phppo.cdc.gov/phtn/botulism/alaska/alaska.asp
Accessed 2003
16
Townes J M, Cieslak P R, Hatheway C L et al..
An outbreak of type A botulism associated with a commercial cheese sauce.
Ann Intern Med.
1996;
125
558-563
17
Shapiro R L, Hatheway C, Becher J, Swerdlow D L.
Botulism surveillance and emergency response.
JAMA.
1997;
278
433-435
18
Hayes M T, Soto O, Ruoff K L.
Case records of the Massachusetts General Hospital: case 22-1997.
N Engl J Med.
1997;
337
184-190
19
Angulo F J, Getz J, Taylor J P et al..
A large outbreak of botulism: the hazardous baked potato.
J Infect Dis.
1998;
178
172-177
20
Brown L W.
Infant botulism.
Adv Pediatr.
1981;
28
141-157
21
Goode G B, Shearn D L.
Botulism. A case with associated sensory abnormalities.
Arch Neurol.
1982;
39
55
22
Kuruoglu R, Cengiz B, Tokcaer A.
Botulism with sensory symptoms diagnosed by neuromuscular transmission studies associated with edrophonium responsiveness.
Electromyogr Clin Neurophysiol.
1996;
36
477-480
23
Martinez-Castrillo J D, Del Real M A, Hernandex Gonzalez A et al..
Botulism with sensory symptoms: a second case.
J Neurol Neurosurg Psychiatry.
1991;
54
844-845
24
Girlanda P, Vita G, Nicolosi C et al..
Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.
J Neurol Neurosurg Psychiatry.
1992;
55
844-845
25
Jenzer G, Mumenthaler M, Ludin H P, Robert F.
Autonomic dysfunction in botulism B: a clinical report.
Neurology.
1975;
25
150-153
26
Chen J T, Chen C C, Lin K P et al..
Botulism: heart rate variation, sympathetic skin responses, and plasma norepinephrine.
Can J Neurol Sci.
1999;
26
123-126
27
Duchen L W, Strich S J.
The effects of botulism toxin on the pattern of innervation of skeletal muscle in the mouse.
Q J Exp Physiol Cogn Med Sci.
1968;
53
84-89
28
Eleopra R, Tugnoli V, Rossetto O et al..
Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.
Neurosci Lett.
1998;
256
135-138
29
Uncini A, Lugarosi A.
Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block.
Muscle Nerve.
1999;
22
640-644
30
Shapiro B E, Soto O, Shafqat S, Blumenfeld H.
Adult botulism.
Muscle Nerve.
1997;
20
100-102
31
Cherington M.
Electrophysiologic methods as an aid in diagnosis of botulism: a review.
Muscle Nerve.
1982;
5
S28-S29
32
Ryan D W, Cherington M.
Human type A botulism.
JAMA.
1971;
216
513-514
33
Edell T A, Sullivan C P, Osborn K M et al..
Wound botulism associated with a positive tensilon test.
West J Med.
1983;
139
218-219
34
Pickett J B, Berg B, Chaplin E, Brunstetter-Shafer M A.
Syndrome of botulism in infancy: clinical and electrophysiologic study.
N Engl J Med.
1976;
295
770-772
35
Arnon S S.
Infant botulism: anticipating the second decade.
J Infect Dis.
1986;
154
201-205
36
Schmidt R D, Schmidt T W.
Infant botulism: a case series and review of the literature.
J Emerg Med.
1992;
10
713-718
37
Kothare S V, Kassner E G.
Infant botulism: a rare cause of colonic ileus.
Pediatr Radiol.
1995;
25
24-26
38
Tanki M G, Gabay M P.
Association between honey consumption and infant botulism.
Pharmacotherapy.
2002;
22
1479-1483
39
Ravid S, Maytal J, Eviatar L.
Biphasic course of infant botulism.
Pediatr Neurol.
2000;
23
338-340
40
Schechter R.
Infant botulism: a brief overview.
Anaerobe.
1999;
5
161-164
41
Underwook K, Deakers T W, Newth C J, Mitchell W G.
Infant botulism: a 26-year experience in the pediatric intensive care unit.
Crit Care Med.
2003;
31(suppl)
, Abstract
531
42
Bennett A M, Perkins S D, Holley J L.
DNA vaccination protects against botulinum neurotoxin F.
Vaccine.
2003;
21
3110-3117
43
Midura T F.
Update: infant botulism.
Clin Microbiol Rev.
1996;
9
119-125
44
Armada M, Love S, Barrett E et al..
Foodborne botulism in a six-month old infant caused by home-canned baby food.
Ann Emerg Med.
2003;
42(2)
226-229
45
MacDonald K L, Rutherford G W, Friedman S M et al..
Botulism and botulism-like illness in chronic drug abusers.
Ann Intern Med.
1985;
102
616-618
46
Mandler R N, Maselli R A.
Stimulated single-fiber electromyography in wound botulism.
Muscle Nerve.
1996;
19
1171-1173
47
Chang G Y, Ganguly G.
Early antitoxin treatment in wound botulism results in better outcome.
Eur Neurol.
2003;
49
151-153
48
Kudrow D B, Henry D A, Haska D A et al..
Botulism associated with Clostridium botulinum sinusitis after intranasal cocaine abuse.
Ann Intern Med.
1988;
109
984-985
49 Cherington M. Treatment of botulism and wound botulism. In: Balows A, DeHaan RM, Dowell VR, Guze LB Anaerobic Bacteria: Role in Disease. Springfield; Charles C. Thomas 1974: 287-294
50
Park J-B, Simpson L L.
Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component.
Infect Immun.
2003;
71
1147-1154
51
Cherington M.
Botulism.
Semin Neurol.
1990;
10
27-31
52
Technical Briefs .
Botulism: information from the World Health Organization.
J Environ Health.
2003;
65
51-52
53
Chia J K, Clark J G, Ryan C A, Pollack M.
Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum
.
N Engl J Med.
1986;
315
239-241
54
Kobayashi H, Fujisawa K, Saito Y et al..
A botulism case of a 12-year-old girl caused by intestinal colonization of Clostridium botulinum type Ab.
Jpn J Infect Dis.
2003;
56
73-74
55
Bakheit A M, Ward C D, McLellan D L.
Generalised botulism-like syndrome after intramuscular injections of botulinum type A: a report of two cases.
J Neurol Neurosurg Psychiatry.
1997;
62
198
56
Bhatia K P, Munchau A, Thompson P D et al..
Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases.
J Neurol Neurosurg Psychiatry.
1999;
67
90-93
57
Tugnoli V, Eleopra R, Quatrale R et al..
Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis.
Br J Dermatol.
2002;
147
808-809
58
Girlanda P, Vita G, Nicolosi C et al..
Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.
J Neurol Neurosurg Psychiatry.
1992;
55
844-845
59
Lange D J, Brin M F, Warner C L et al..
Distant effects of local injection of botulinum toxin.
Muscle Nerve.
1987;
10
552-555
60
Olney R K, Aminoff M J, Gelb D J, Lowenstein D H.
Neuromuscular effects distant from the site of botulinum neurotoxin injections.
Neurology.
1988;
38
1780-1783
61
Kessler K R, Skutta M, Benecke R.
Long term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency.
J Neurol.
1999;
246
265-274
62
Ross M H, Charness M E, Sudarsky L, Logigian E L.
Treatment of occupational cramp with botulinum toxin: diffusion of toxin to adjacent noninjected muscles.
Muscle Nerve.
1997;
20
593-598
63
Dressler D, Benecke R.
Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
Eur Neurol.
2003;
49
34-38
64
Dowell V R, McCrosky L M, Hatheway C L et al..
Coproexamination for botulium toxin and Clostridium botulinum
.
JAMA.
1977;
238
1829-1832
65
Cornblath D R, Sladky J T, Sumner A J.
Clinical electrophysiology of infantile botulism.
Muscle Nerve.
1983;
6
448-452
66
Gutmann L, Bodensteiner J, Gutierrez A.
Electrodiagnosis of botulism.
J Pediatr.
1992;
121
835
67
Fakadej A V, Gutmann L.
Prolongation of post-tetanic facilitation in infant botulism.
Muscle Nerve.
1982;
5
727-729
68
Girlanda P, Dattola R, Messina C.
Single fibre EMG in 6 cases of botulism.
Acta Neurol Scand.
1983;
67
118-123
69
Schiller H H, Stalberg E.
Human botulism studied with single-fiber electromyography.
Arch Neurol.
1978;
35
346-349
70
Hughes J M, Tacket C O.
“Sausage poisoning” revisited.
Arch Intern Med.
1983;
143
425-427
71
Atabek M E, Yavuz H, Oran B et al..
Plasmapheresis as an adjunct treatment in severe botulism.
Intensive Care Med.
2002;
28
814
72
Robinson R F.
Management of botulism.
Ann Pharmacother.
2003;
37
127-131
73
Vahdani P, Pourshafie M R, Aminzadeh Z.
Treatment of two unusual cases of type A and E botulism following consumption of salted fish.
Intensive Care Med.
2002;
28
1189
74
Amersdorfer P, Wong C, Smith T et al..
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.
Vaccine.
2002;
20
1640-1648
75
Nowakowski A, Wang C, Powers D B et al..
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.
Proc Natl Acad Sci USA.
2002;
99
11346-11350
76 Cherington M. Botulism. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE Neuromuscular Disorders in Clinical Practice. Boston; Butterworth Heinemann 2002: 942-952
77
Jankovic J, Vuong M A, Ahsan J.
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.
Neurology.
2003;
60
1186-1188
78
Dodick D W.
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Headache.
2003;
43
S25-S33
79
Rohrich R J.
Completing the cosmetic surgery cycles: it takes a village.
Plast Reconstr Surg.
1999;
103
585-587
80
Vaezi M F, Richter J E, Wilcox C M et al..
Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomized trial.
Gut.
1999;
44
231-239
81
Brisinda G, Maria G, Bentivoglo A R et al..
A comparison of injection of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure.
N Engl J Med.
1999;
341
65-69
82
Maria G, Brisinda G, Civello I M et al..
Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.
Urology.
2003;
62
259-265
83
Hallett M.
One man's poison: clinical applications of botulinum toxin.
N Engl J Med.
1999;
341
118-120
84
Eleopra R, Tugnoli V, Quatrale R et al..
Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
Clin Neurophysiol.
2002;
113
1258-1264
85
Brashear A, McAfee A L, Kuhn E R, Ambrosius W T.
Treatment with botulinum toxin type B for upper-limb spasticity.
Arch Phys Med Rehabil.
2003;
84
103-107
86
Turton K, Chaddock J A, Acharya K R.
Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.
Trends Biochem Sci.
2002;
27
552-558
Michael CheringtonM.D.
Lightning Data Center, St. Anthony Hospital
4231 West 16th Avenue, Denver, CO 80204